EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen,Robert Landewé,Ferdinand C. Breedveld,Maya H Buch,Maya H Buch,Gerd R Burmester,Maxime Dougados,Paul Emery,Paul Emery,Cécile Gaujoux-Viala,Laure Gossec,Jackie L Nam,Jackie L Nam,Sofia Ramiro,Kevin L. Winthrop,Maarten de Wit,Daniel Aletaha,Neil Betteridge,Johannes W. J. Bijlsma,Maarten Boers,Frank Buttgereit,Bernard Combe,Maurizio Cutolo,Nemanja Damjanov,Johanna M. W. Hazes,Marios Kouloumas,Tore K Kvien,Xavier Mariette,Karel Pavelka,Piet L. C. M. van Riel,Andrea Rubbert-Roth,Marieke Scholte-Voshaar,David Scott,T. Sokka-Isler,John B. Wong,Désirée van der Heijde +35 more
TLDR
These recommendations intend informing rheumatologists, patients, national rheumology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.Abstract:
In this article, the 2010 European League against Rheumatism (EULAR) recommendations for the management of rheumatoid arthritis (RA) with synthetic and biological disease-modifying antirheumatic drugs (sDMARDs and bDMARDs, respectively) have been updated. The 2013 update has been developed by an international task force, which based its decisions mostly on evidence from three systematic literature reviews (one each on sDMARDs, including glucocorticoids, bDMARDs and safety aspects of DMARD therapy); treatment strategies were also covered by the searches. The evidence presented was discussed and summarised by the experts in the course of a consensus finding and voting process. Levels of evidence and grades of recommendations were derived and levels of agreement (strengths of recommendations) were determined. Fourteen recommendations were developed (instead of 15 in 2010). Some of the 2010 recommendations were deleted, and others were amended or split. The recommendations cover general aspects, such as attainment of remission or low disease activity using a treat-to-target approach, and the need for shared decision-making between rheumatologists and patients. The more specific items relate to starting DMARD therapy using a conventional sDMARD (csDMARD) strategy in combination with glucocorticoids, followed by the addition of a bDMARD or another csDMARD strategy (after stratification by presence or absence of adverse risk factors) if the treatment target is not reached within 6 months (or improvement not seen atread more
Citations
More filters
Journal ArticleDOI
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
Jasvinder A. Singh,Daniel E. Furst,Aseem Bharat,Jeffrey R. Curtis,Arthur Kavanaugh,Joel M. Kremer,Larry W. Moreland,James O'Dell,Kevin L. Winthrop,Timothy Beukelman,S. Louis Bridges,W. Winn Chatham,Harold E. Paulus,Maria E. Suarez-Almazor,Claire Bombardier,Maxime Dougados,Dinesh Khanna,Charles M. King,Amye L. Leong,Eric L. Matteson,John T. Schousboe,Eileen Moynihan,Karen S. Kolba,Archana Jain,Elizabeth R. Volkmann,Harsh Agrawal,Sangmee Bae,Amy S. Mudano,Nivedita M. Patkar,Kenneth G. Saag +29 more
TL;DR: The 2012 ACR RA recommendations were developed by two expert panels: a non-voting working group and Core Expert Panel of clinicians and methodologists responsible for the selection of the relevant topic areas to be considered, the systematic literature review, and the evidence synthesis.
Journal ArticleDOI
2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis
Désirée van der Heijde,Sofia Ramiro,Robert Landewé,Xenofon Baraliakos,Filip Van den Bosch,Alexandre Sepriano,Alexandre Sepriano,Andrea Regel,Adrian Ciurea,Hanne Dagfinrud,Maxime Dougados,Maxime Dougados,Floris A. van Gaalen,Pál Géher,Irene E. van der Horst-Bruinsma,Robert D. Inman,Merryn Jongkees,Uta Kiltz,Tore K Kvien,Pedro Machado,Helena Marzo-Ortega,Anna Molto,Anna Molto,Victoria Navarro-Compán,Salih Ozgocmen,Fernando Pimentel-Santos,John D. Reveille,Martin Rudwaleit,Martin Rudwaleit,J. Sieper,Percival D. Sampaio-Barros,Dieter Wiek,Jürgen Braun +32 more
TL;DR: The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA and three overarching principles and 13 recommendations deal with surgery and spinal fractures.
Journal ArticleDOI
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
Josef S Smolen,Ferdinand C. Breedveld,Gerd R Burmester,Vivian P. Bykerk,Maxime Dougados,Paul Emery,Tore K Kvien,M Victoria Navarro-Compán,Susan Oliver,Monika Schoels,Marieke Scholte-Voshaar,Tanja Stamm,Michaela Stoffer,Tsutomu Takeuchi,Daniel Aletaha,Jose Louis Andreu,Martin Aringer,Martin J. Bergman,Neil Betteridge,H. Bijlsma,Harald Burkhardt,Mario H. Cardiel,Bernard Combe,Patrick Durez,João Eurico Fonseca,A. Gibofsky,Juan J. Gomez-Reino,Winfried Graninger,Pekka Hannonen,Boulos Haraoui,Marios Kouloumas,Robert Landewé,Emilio Martín-Mola,Peter Nash,Mikkel Østergaard,Andrew J. K. Östör,Pam Richards,T. Sokka-Isler,Carter Thorne,Athanasios G. Tzioufas,Ronald F van Vollenhoven,Martinus de Wit,Désirée van der Heijde +42 more
TL;DR: The 4 overarching principles and 10 recommendations are based on stronger evidence than before and are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA.
Journal ArticleDOI
COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.
Tomasz J. Guzik,Tomasz J. Guzik,Saidi A Mohiddin,Anthony Dimarco,Vimal Patel,K Savvatis,Federica M. Marelli-Berg,Meena S. Madhur,Maciej Tomaszewski,Pasquale Maffia,Pasquale Maffia,Fulvio D'Acquisto,Stuart A. Nicklin,Ali J. Marian,Ryszard Nosalski,Ryszard Nosalski,Eleanor Murray,Bartłomiej Guzik,Colin Berry,Rhian M. Touyz,Reinhold Kreutz,Dao Wen Wang,David Bhella,Orlando Sagliocco,Filippo Crea,E. Thomson,Iain B. McInnes +26 more
TL;DR: While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis, Hence, patients should not discontinue their use.
Journal ArticleDOI
Diagnosis and Management of Rheumatoid Arthritis: A Review.
Daniel Aletaha,Josef S Smolen +1 more
TL;DR: A treat-to-target strategy aimed at reducing disease activity by at least 50% within 3 months and achieving remission or low disease activity within 6 months, with sequential drug treatment if needed, can prevent RA-related disability.
References
More filters
Journal Article
The when and how of biologic agent withdrawal in rheumatoid arthritis: learning from large randomised controlled trials.
Arthur Kavanaugh,Josef S. Smolen +1 more
TL;DR: Data is starting to emerge, much of it from controlled trials, that can provide some guidance as to which patients might be the best candidates for such an approach to rheumatoid arthritis, and will provide answers to the key questions that remain concerning this important potential paradigm shift.
Journal ArticleDOI
OP0022 Abatacept sc versus adalimumab on background methotrexate in RA: One year results from the ample study
Michael Schiff,Roy Fleischmann,Michael E. Weinblatt,R. Valente,D. van der Heijde,Gustavo Citera,Cathy Zhao,M. Maldonado +7 more
TL;DR: This first head-to-head study in RA patients comparing biologic DMARD agents demonstrated that SC ABA is comparable to ADA in efficacy (by non-inferiority analysis) with similar kinetics of response and inhibition of radiographic progression at one year.
Journal ArticleDOI
Disease‐modifying anti‐rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community‐based practice
TL;DR: The aim was to examine the spectrum of disease activity and usage of disease‐modifying anti‐rheumatic drugs (DMARD) in rheumatoid arthritis patients seen over a period of 12 months in community‐based r heumatology practice.
Journal Article
A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission
Katerina Chatzidionysiou,Carl Turesson,Annika Teleman,Ann Knight,Elisabet Lindqvist,Per Larsson,L Cöster,Barbro Rydberg,Ronald F van Vollenhoven,Mikael Heimbürger +9 more
TL;DR: A Multicenter, Randomized, Controlled, Open-Label Pilot Study of the Feasibility of Discontinuation of Adalimumab in Rheumatoid Arthritis Patients in Stable Clinical Remission finds that discontinuation may be feasible.
Related Papers (5)
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh,Kenneth G. Saag,S. Louis Bridges,Elie A. Akl,Raveendhara R. Bannuru,Matthew C. Sullivan,Elizaveta E. Vaysbrot,Christine McNaughton,Mikala C. Osani,Robert H. Shmerling,Jeffrey R. Curtis,Daniel E. Furst,Deborah Parks,Arthur Kavanaugh,James R. O'Dell,Charles H. King,Amye Leong,Eric L. Matteson,John T. Schousboe,Barbara E. Drevlow,Seth Ginsberg,James Grober,E. William St. Clair,Elizabeth A. Tindall,Amy S. Miller,Timothy E. McAlindon +25 more
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.
Frank C. Arnett,Steven M. Edworthy,Daniel A. Bloch,Dennis J. McShane,James F. Fries,Norman S. Cooper,L. A. Healey,Stephen R. Kaplan,Matthew H. Liang,Harvinder S. Luthra,Thomas A. Medsger,Donald M. Mitchell,David H. Neustadt,Robert S. Pinals,Jane G. Schaller,John T. Sharp,Ronald L. Wilder,Gene G. Hunder +17 more
2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.
Daniel Aletaha,Tuhina Neogi,Alan J. Silman,Julia Funovits,David T. Felson,Clifton O. Bingham,Neal S. Birnbaum,Gerd Burmester,Vivian P. Bykerk,Marc D. Cohen,Bernard Combe,Karen H. Costenbader,Maxime Dougados,Paul Emery,Gianfranco Ferraccioli,Johanna M. W. Hazes,Kathryn Hobbs,Tom W J Huizinga,Arthur Kavanaugh,Jonathan Kay,Tore K Kvien,Timothy J. Laing,Philip J. Mease,Henri A Ménard,Larry W. Moreland,Raymond L. Naden,Theodore Pincus,Josef S Smolen,Ewa Stanislawska-Biernat,Deborah P M Symmons,Paul P. Tak,Katherine S. Upchurch,Jiří Vencovský,Frederick Wolfe,Gillian A. Hawker +34 more
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S Smolen,Daniel Aletaha,J. Bijlsma,Ferdinand C. Breedveld,Dimitrios T. Boumpas,Gerd R Burmester,Bernard Combe,Maurizio Cutolo,Maarten de Wit,Maxime Dougados,Paul Emery,A. Gibofsky,Juan J. Gomez-Reino,Boulos Haraoui,Joachim Kalden,Edward C. Keystone,Tore K Kvien,Iain B. McInnes,Emilio Martín-Mola,Carlomaurizio Montecucco,Monika Schoels,Désirée van der Heijde +21 more
2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis
Jasvinder A. Singh,Daniel E. Furst,Aseem Bharat,Jeffrey R. Curtis,Arthur Kavanaugh,Joel M. Kremer,Larry W. Moreland,James O'Dell,Kevin L. Winthrop,Timothy Beukelman,S. Louis Bridges,W. Winn Chatham,Harold E. Paulus,Maria E. Suarez-Almazor,Claire Bombardier,Maxime Dougados,Dinesh Khanna,Charles M. King,Amye L. Leong,Eric L. Matteson,John T. Schousboe,Eileen Moynihan,Karen S. Kolba,Archana Jain,Elizabeth R. Volkmann,Harsh Agrawal,Sangmee Bae,Amy S. Mudano,Nivedita M. Patkar,Kenneth G. Saag +29 more